TeloVac Trial - Frequently asked questions

Q. If I have received chemotherapy before, am I eligible for the TeloVac trial?

Unfortunately any history of previous chemotherapy (including gemcitabine and/or capecitabine) excludes patients from the trial as it may affect the outcome of the trial.

Q. My hospital is not involved in the TeloVac trial, what can I do?

Ask your consultant to find the closest hospital involved in the TeloVac trial and discuss your options of being transferred.

Q. If I have had surgery (resection), am I eligible?

The tumour must be inoperable at the time of study screening. This can either be the tumour which was first diagnosed or a tumour that has progressed since previous surgery for pancreatic cancer.

Q. How many people have received the vaccine? How safe is it?

To date, more than a 100 patients have been vaccinated with GV1001 either alone or in combination with a shorter peptide that activates cytotoxic T-cells. The overall safety picture emerging from early phase I/II trials is that GV1001 can be administered safely to human subjects.

Q. What are the side effects of the vaccine?

Side effects of the vaccine that you may encounter are:

• mild temporary pain or rash at the injection site should be expected
• Flu like symptoms e.g. muscle aches and pains and a temperature. Paracetamol usually controls this.